Skip to main content

Advertisement

SpringerLink
Log in

Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Reference

  1. Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798

    Article  PubMed  CAS  Google Scholar 

  2. Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799–807

    Article  PubMed  CAS  Google Scholar 

  3. Heine A, Brossart P, Wolf D (2013) Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122:3843–3844

    Article  PubMed  CAS  Google Scholar 

  4. Shen CH, Hwang CE, Chen YY, Chen CC (2014) Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol 93:1075–1076

    Article  PubMed  Google Scholar 

  5. Wathes R, Moule S, Milojkovic D (2013) Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med 369:197–198

    Article  PubMed  CAS  Google Scholar 

  6. Goldberg RA, Reichel E, Oshry LJ (2013) Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med 369:681–683

    Article  PubMed  CAS  Google Scholar 

  7. Wysham NG, Sullivan DR, Allada G (2013) An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 143:1478–1479

    Article  PubMed  Google Scholar 

  8. O'Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368:161–170

    Article  PubMed  Google Scholar 

  9. Heine A, Held SA, Daecke SN et al (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122:1192–1202

    Article  PubMed  CAS  Google Scholar 

  10. Schonberg K, Rudolph J, Vonnahme M et al (2015) JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res 75:2187–2199

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Department of Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan

    Chih-Cheng Chen, Yi-Yang Chen & Cih-En Huang

  2. College of Medicine, Chang Gung University, Tao-Yuan, Taiwan

    Chih-Cheng Chen

Authors
  1. Chih-Cheng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi-Yang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cih-En Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chih-Cheng Chen.

Ethics declarations

Conflicts of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, CC., Chen, YY. & Huang, CE. Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib. Ann Hematol 95, 361–362 (2016). https://doi.org/10.1007/s00277-015-2532-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2532-7

Keywords

Search

Navigation